Eyelash Growth from Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes
Open accessAbstract
Objective To determine whether bimatoprost (Lumigan, Allergan Inc., Irvine, CA) causes increased lash length when used in gel suspension applied to the base of the eyelashes. Design Randomized controlled trial. Participants Nineteen subjects were enrolled. Methods Subjects recruited from the Bascom Palmer Eye Institute were screened, and those who met inclusion criteria were enrolled. Each participant received 2 vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with Gonak gel (Akorn Inc., Lake Forest, IL) and labeled "right eye" and "left eye" according to randomization. The suspension was applied to the upper eyelid eyelashes every evening on the designated eye for 6 weeks. Main outcome measures Lash length was measured with a caliper at enrollment, at weekly intervals during the application of the gel, and at 1 and 3 months after discontinuation of its use. Visual acuity, ocular symptoms, intraocular pressure, and photographs were documented at these same intervals. Results The mean eyelash growth from baseline in the bimatoprost group was 2.0 mm versus a mean of 1.1 mm in the placebo group, which was a statistically significant difference (P=0.009). The average intraocular pressure decreased equally in both groups (2 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects. Conclusions Our data showed an increase in eyelash length with the use of bimatoprost in gel suspension, suggesting the product's eyelash-lengthening properties.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bimatoprost 0.03% has enhanced eyelash prominence in clinical trials enrolling mostly Caucasian subjects.
“Bimatoprost 0.03 % has enhanced eyelash prominence in clinical trials enrolling mostly Caucasian subjects.”
From Bimatoprost for Eyelash Growth in Japanese Subjects: Two Multicenter Controlled Studies (2014) · cites this paper as [16]
The Methods describe a randomized trial using bimatoprost 0.03% in a gel suspension, and the Results report significantly greater eyelash lengthening than with control gel. The Results identify the 19 participants as female but do not report their race or ethnicity, so the claim that subjects were mostly Caucasian is not supported by our copy. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 16
- [1]Johnstone MA Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost Am J Ophthalmol 1997 124 544 7 9323945
- [2]Sugimoto M Sugimoto M Uji Y Quantitative analysis of eyelash lengthening following topical latanoprost therapy Can J Ophthalmol 2002 37 342 5 12422916
- [3]Chiba T Kashiwagi K Ishijima K A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost Jpn J Ophthalmol 2004 48 141 7 15060793
- [4]Elgin U Batman A Berker N Ilhan B The comparison of eyelash lengthening effect of latanoprost therapy in adults and children Eur J Ophthalmol 2006 16 247 50 16703542
- [5]Uno H Zimbric ML Albert DM Stjernschantz J Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macaque: a pilot study Acta Derm Venereol 2002 82 7 12 12013211
- [6]Mansberger SL Cioffi GA Eyelash formation secondary to latanoprost treatment in a patient with alopecia Arch Ophthalmol 2000 118 718 9 10815168
- [7]Michelet JF Commo S Billoni N Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect J Invest Dermatol 1997 108 205 9 9008235
- [8]Torii E Segi E Sugimoto Y Expression of prostaglandin E(2) receptor subtypes in mouse hair follicles Biochem Biophys Res Commun 2002 290 696 700 11785955
- [9]Noecker RS Dirks MS Choplin NT Bimatoprost/Latanoprost Study Group A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma Am J Ophthalmol 2003 135 55 63 12504698
- [10]Eisenberg DL Toris CB Camras CB Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs Surv Ophthalmol 2002 47 suppl S105 15 12204706
- [11]Tosti A Pazzaglia M Voudouris S Tosti G Hypertrichosis of the eyelashes caused by bimatoprost J Am Acad Dermatol 2004 51 suppl S149 50 15577756
- [13]Fleiss JL Statistical Methods for Rates and Proportions 2 New York Wiley 1981 223 4
- [16]Allergan announces U.S. Food And Drug Administration (FDA) approval of Latisse--first and only treatment approved by the FDA for hypotrichosis of eyelashes [press release] Irvine, CA Allergan December 26 2008 Available at: http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=356159 Accessed May 26, 2009
- [17]Grierson I Jonsson M Cracknell K Latanoprost and pigmentation Jpn J Ophthalmol 2004 48 602 12 15592791
- [18]Herndon LW Williams RD Wand M Asrani S Increased periocular pigmentation with ocular hypotensive lipid use in African Americans Am J Ophthalmol 2003 135 713 4 12719085
- [19]Sherwood M Brandt J Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure Surv Ophthalmol 2001 45 suppl S361 8 11434939
Cited by
Sorted by citations
Bimatoprost for Eyelash Growth in Japanese Subjects: Two Multicenter Controlled Studies
Harii, K., Arase, S., Tsuboi, R., Weng, E., Daniels, S., & VanDenburgh, A. (2014) · Aesthetic Plastic Surgery · doi:10.1007/s00266-014-0293-7 · Cited by 29 · see citing works
- Authors
- Wester, S. T., Lee, W. W., & Shi, W.
- Affiliations
- University of Miami (US)
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 117
- Issue
- 5
- Pages
- 1024-1031
- ISSN
- 0161-6420 (ISSN-L)
- PMC
- PMC2864326
- OpenAlex
- W2019720349
- Cited by
- 39
- References
- 0
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 4 · 2023: 1 · 2022: 4 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 4 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 5 · 2012: 3
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Eye Institute
- Research to Prevent Blindness
- Topics
- Health Sciences › Medicine › Urology › Hair Growth and Disorders
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ocular Surface and Contact Lens
- Keywords
- bimatoprost, eyelash growth, prostamide, intraocular pressure, visual acuity
- MeSH terms
- Bimatoprost, Adult, Aged, Amides, Cloprostenol, Double-Blind Method, Eye Color, Eyelashes, Female, Gels, Humans, Hypertrichosis, Intraocular Pressure, Middle Aged, Prospective Studies, Visual Acuity, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
